Recherches & Rapports
14 sept. 2026•1 min de lecture
Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.
Recherches & Rapports
30 août 2026•1 min de lecture
Targeted Therapies Transform Atopic Dermatitis Treatment
Emerging targeted drugs are shifting atopic dermatitis care from symptom control to broader quality‑of‑life improvements.